JP Morgan Chase’s XBiotech XBIT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $218 | Sell |
96
-1,032
| -91% | -$2.5K | ﹤0.01% | 7245 |
|
|
2025
Q4 | $2.69K | Sell |
1,128
-1,254
| -53% | -$3.09K | ﹤0.01% | 6897 |
|
|
2025
Q3 | $6.34K | Sell |
2,382
-6,499
| -73% | -$19.2K | ﹤0.01% | 6733 |
|
|
2025
Q2 | $26.4K | Sell |
8,881
-21,304
| -71% | -$61.9K | ﹤0.01% | 6108 |
|
|
2025
Q1 | $97.8K | Buy |
30,185
+15,561
| +106% | +$53.7K | ﹤0.01% | 5580 |
|
|
2024
Q4 | $57.8K | Buy |
14,624
+5,930
| +68% | +$40.4K | ﹤0.01% | 5959 |
|
|
2024
Q3 | $67.2K | Buy |
8,694
+770
| +10% | +$5.06K | ﹤0.01% | 5878 |
|
|
2024
Q2 | $40.7K | Buy |
7,924
+7,886
| +20,753% | +$60.8K | ﹤0.01% | 5938 |
|
|
2024
Q1 | $309 | Hold |
38
| – | – | ﹤0.01% | 6771 |
|
|
2023
Q4 | $152 | Hold |
38
| – | – | ﹤0.01% | 7078 |
|
|
2023
Q3 | $157 | Hold |
38
| – | – | ﹤0.01% | 6868 |
|
|
2023
Q2 | $226 | Hold |
38
| – | – | ﹤0.01% | 6621 |
|
|
2023
Q1 | $0 | Hold |
38
| – | – | ﹤0.01% | 7279 |
|
|
2022
Q4 | $0 | Sell |
38
-11,098
| -100% | -$37.8K | ﹤0.01% | 7050 |
|
|
2022
Q3 | $40K | Sell |
11,136
-3,672
| -25% | -$17.3K | ﹤0.01% | 5620 |
|
|
2022
Q2 | $83K | Sell |
14,808
-285
| -2% | -$1.92K | ﹤0.01% | 5495 |
|
|
2022
Q1 | $131K | Buy |
15,093
+6,360
| +73% | +$63.8K | ﹤0.01% | 5393 |
|
|
2021
Q4 | $98K | Buy |
8,733
+616
| +8% | +$8.02K | ﹤0.01% | 5697 |
|
|
2021
Q3 | $105K | Sell |
8,117
-6,222
| -43% | -$99.1K | ﹤0.01% | 5538 |
|
|
2021
Q2 | $238K | Sell |
14,339
-11,164
| -44% | -$189K | ﹤0.01% | 5149 |
|
|
2021
Q1 | $438K | Buy |
25,503
+19,065
| +296% | +$356K | ﹤0.01% | 4750 |
|
|
2020
Q4 | $100K | Buy |
6,438
+1,118
| +21% | +$20.6K | ﹤0.01% | 4993 |
|
|
2020
Q3 | $101K | Buy |
5,320
+476
| +10% | +$8.22K | ﹤0.01% | 4690 |
|
|
2020
Q2 | $67K | Buy |
4,844
+567
| +13% | +$7.97K | ﹤0.01% | 4725 |
|
|
2020
Q1 | $46K | Sell |
4,277
-1,980
| -32% | -$32.2K | ﹤0.01% | 4751 |
|
|
2019
Q4 | $117K | Buy |
6,257
+37
| +0.6% | +$476 | ﹤0.01% | 4845 |
|
|
2019
Q3 | $65K | Buy |
6,220
+1,631
| +36% | +$13.3K | ﹤0.01% | 5059 |
|
|
2019
Q2 | $34K | Buy |
+4,589
| New | +$39.9K | ﹤0.01% | 5316 |
|
|
2018
Q2 | – | Sell |
-3,890
| Closed | -$21K | – | 5721 |
|
|
2018
Q1 | $21K | Sell |
3,890
-279
| -7% | -$1.28K | ﹤0.01% | 5073 |
|
|
2017
Q4 | $16K | Buy |
+4,169
| New | +$17.5K | ﹤0.01% | 5196 |
|
|
2017
Q2 | – | Sell |
-24,840
| Closed | -$410K | – | 5260 |
|
|
2017
Q1 | $410K | Buy |
24,840
+21,616
| +670% | +$283K | ﹤0.01% | 3798 |
|
|
2016
Q4 | $33K | Sell |
3,224
-1,903
| -37% | -$25.3K | ﹤0.01% | 4615 |
|
|
2016
Q3 | $69K | Buy |
5,127
+4,902
| +2,179% | +$71.9K | ﹤0.01% | 3955 |
|
|
2016
Q2 | $5K | Buy |
+225
| New | +$3.25K | ﹤0.01% | 4462 |
|
Other funds holding XBIT
VCM
RC
BCM
VFT
JP Morgan Chase's XBIT Position: Q1 2026 in Review
JP Morgan Chase reduced its XBiotech (XBIT) stake by 91% in Q1 2026, selling an estimated $2.5K and leaving 96 shares worth $218. The position accounts for ﹤0.01% of the portfolio, ranked #7245.
JP Morgan Chase first reported a position in XBIT in Q2 2016 and has held it in 34 quarters since. The position peaked at $438K in Q1 2021. 37 funds tracked by Wall St. Rank hold XBIT as of Q1 2026.
- JP Morgan Chase held 96 shares of XBiotech worth $218 as of Q1 2026.
- JP Morgan Chase sold 1,032 XBiotech shares in Q1 2026, an estimated $2.5K.
- XBiotech made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7245 holding.
- JP Morgan Chase first reported a position in XBiotech in Q2 2016 and has held it in 34 quarters since.
- JP Morgan Chase's XBiotech position peaked at $438K in Q1 2021.
- 37 funds tracked by Wall St. Rank held XBiotech as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.